AstraZeneca plc. (NASDAQ: AZN) has moved to calm the storm over a new strain of Coronavirus that continues to cause havoc. The giant drug maker has confirmed that its vaccine has what it takes to combat the new strain first detected in the U.K.
COVID Vaccine
Chief Executive Officer, Pascal Soriot, remains confident of the vaccine being effective in tackling the vaccine. Reports making circles indicate that the company’s researchers have discovered a winning formula to make the vaccine as effective as Pfizer and Moderna vaccines.
Developed in partnership with Oxford University, the vaccine is yet to secure regulatory approval. However, there is growing confidence that the AstraZeneca vaccine could be approved as early as this week. While the vaccine was also believed not to be as effective as Pfizer’s or Moderna’s, given its 70% efficacy, the company says it has figured out the winning formula.
However, there is a growing concern about whether the current vaccines have what it takes to combat the new strain, which is 70% more transmissible. A good number of countries have already halted travel from the U.K, awaiting further information about the new coronavirus strain. Moderna has also moved to quash concerns about the new strain reiterating that its vaccine is more than capable of protecting people from the new strain.
AstraZeneca has come under pressure in recent weeks, tanking to seven-month lows. The decline comes even on the company reiterating its vaccine is 70% more effective in combating the coronavirus. Its sentiments in the market appear to have taken a hit on the company lagging behind in securing Pfizer and Moderna's regulatory approval.
Alexion Acquisition
Separately, the company has confirmed plans to acquire Alexion pharmaceutical as it seeks to strengthen its exposure to rare disease treatment. The company is to pay $39 billion in a combination of cash and stock, with Alexion shareholders on course to receive about $175 a share held.
If approved by regulators, Alexion Shareholders will end up owning 15% of AstraZeneca. The shareholders will also receive $60 in cash. The deal represents a 45% premium.